{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:29:31Z","timestamp":1793773771008,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:00:45Z","timestamp":1773457245000},"page":"386-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin"],"prefix":"10.1053","volume":"62","author":[{"given":"Katie L.","family":"Thoren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2026.03.006_bib0001","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0003","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease\u2013based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0007","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","article-title":"Endogenous monoclonal immunoglobulins analyzed using the EXENT\u00ae solution and LC-MS","volume":"32","author":"Barnidge","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0009","article-title":"Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement","author":"Nevejan","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","author":"Mills","year":"2015","journal-title":"Methods"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0011","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/clinchem\/hvae179","article-title":"Applications of mass spectrometry proteomic methods to immunoglobulins in the clinical laboratory","volume":"70","author":"Murray","year":"2024","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2021.01.021","article-title":"Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy","volume":"516","author":"Eveillard","year":"2021","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0013","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Kohlhagen","year":"2016","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1373\/clinchem.2018.299461","article-title":"Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry","volume":"65","author":"Sepiashvili","year":"2019","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-019-0180-1","article-title":"A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis","volume":"9","author":"Sharpley","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0016","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry\u2013based assay to monitor M-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0017","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","article-title":"Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients","volume":"20","author":"McDonald","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pharmaceutics17010135","article-title":"Monitoring M-protein, therapeutic antibodies, and polyclonal antibodies in a multiparametric mass spectrometry assay provides insight into therapy response kinetics in patients with multiple myeloma","volume":"17","author":"Wijnands","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0019","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/j.clml.2025.04.017","article-title":"Blood-based measurable residual disease by clonotypic mass spectrometry is prognostic in patients with multiple myeloma undergoing autologous hematopoietic cell transplant","volume":"25","author":"Slade","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0020","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285933","article-title":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","author":"Zhao","year":"2025","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0021","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0022","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0023","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/HS9.0000000000000758","article-title":"Retrospective longitudinal monitoring of multiple myeloma patients by mass spectrometry using archived serum protein electrophoresis gels and de novo sequence analysis","volume":"6","author":"Noori","year":"2022","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0024","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0025","series-title":"Janeway\u2019s immunobiology","author":"Murphy","year":"2017"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100124","article-title":"Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma","volume":"2","author":"Kubicki","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0028","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0029","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0030","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285742","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial","author":"Puig","year":"2024","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0031","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0032","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.4254","article-title":"Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0034","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0036","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0037","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0039","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0042","unstructured":"Mayo Clinic MASSFIX, Insights (n.d.). https:\/\/news.mayocliniclabs.com\/hematology\/plasma-cell-neoplasms\/mayo-clinic-massfix\/ (accessed 05.01.26)."},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0043","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1182\/blood-2022-160249","article-title":"Comparison of the analytical performance of EXENT\u00ae, a mass spectrometry-based assessment of M-protein, to SPEP and NGS-based MRD in multiple myeloma patient samples","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.006_bib0044","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bjh.19589","article-title":"Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells","volume":"205","author":"Ortiz de Landazuri","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:44Z","timestamp":1778728064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632600020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S003719632600020X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}